Compare LODE & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | IMUX |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.0M | 155.8M |
| IPO Year | 2004 | 2013 |
| Metric | LODE | IMUX |
|---|---|---|
| Price | $2.10 | $6.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $43.09 |
| AVG Volume (30 Days) | ★ 1.4M | 392.9K |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.55 | 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,553,796.00 | N/A |
| Revenue This Year | $303.79 | N/A |
| Revenue Next Year | $410.04 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.10 | $0.51 |
| 52 Week High | $4.98 | $17.43 |
| Indicator | LODE | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 24.51 | 24.48 |
| Support Level | N/A | $0.83 |
| Resistance Level | $3.32 | $15.82 |
| Average True Range (ATR) | 0.11 | 0.63 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 5.38 | 0.17 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.